Sterilizing immunity against experimental Helicobacter pylori infection is challenge-strain dependent
The development of a murine model of Helicobacter pylori infection through serial in vivo passage of candidate strains has enabled a quantitative assessment of vaccine efficacy. In this study we compare infection with and protection against challenge from both CagA + type I, and CagA − type II in vi...
Gespeichert in:
Veröffentlicht in: | Vaccine 2001-09, Vol.19 (32), p.4883-4895 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 4895 |
---|---|
container_issue | 32 |
container_start_page | 4883 |
container_title | Vaccine |
container_volume | 19 |
creator | Kleanthous, Harry Tibbitts, Timothy J Gray, Heather L Myers, Gwendolyn A Lee, Cynthia K Ermak, Thomas H Monath, Thomas P |
description | The development of a murine model of
Helicobacter pylori infection through serial in vivo passage of candidate strains has enabled a quantitative assessment of vaccine efficacy. In this study we compare infection with and protection against challenge from both CagA
+ type I, and CagA
− type II in vivo adapted isolates. In vivo passage of a type II
H. pylori isolate resulted in a highly infectious strain (X47-2AL), capable of reproducibly infecting mice to high density (10
7 CFU/g of gastric tissue). Similarly adapted type I strains were found to colonize mice at a significantly lower level (10
4–10
5 CFU/g tissue). Mucosal immunization with recombinant urease (rUre) significantly protected animals against both types. Protection against X47-2AL was characterized by a ≥100-fold (or 2 log) reduction in bacterial density. However, the presence of a residual infection highlighted the inability to achieve sterilizing immunity against this strain. The level of protection appeared independent of challenge dose, and was stable for up to 6 months, all animals exhibiting a low-level residual infection that did not recrudesce with time. Similarly immunized mice challenged with isolates representing the residual infection were also protected, confirming that they did not represent a sub-population of
H. pylori that could escape immunity. Immunization and challenge studies with type I adapted-isolates, demonstrated a similar 2–3 log reduction in the bacterial burden, but that in this instance resulted in sterilizing immunity. These results suggest varied specificity for the murine host by different
Helicobacter strains that can influence the outcome of both infection and immunity. |
doi_str_mv | 10.1016/S0264-410X(01)00248-1 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71145617</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X01002481</els_id><sourcerecordid>18107265</sourcerecordid><originalsourceid>FETCH-LOGICAL-c422t-7b5c4548b00bdb157694632223c5783fa9fe00be1a58ef536a1a7f6add9670ba3</originalsourceid><addsrcrecordid>eNqFkU1v1DAQhi0EotvCTwD5AiqHgMefyalCFVCkShwKEjfLcSaLkeMEO4tYfj1ud0WPPfkwzztjPS8hL4C9BQb63Q3jWjYS2PdzBm8Y47Jt4BHZQGtEwxW0j8nmP3JCTkv5yRhTArqn5ARACSUk3xC8WTGHGP6GtKVhmnYprHvqti6kslL8s9TphGl1kV5hDH7una8JuuzjnAMNaUS_hjnRUKj_4WLEtMWmrLkuoAMumIaafkaejC4WfH58z8i3jx--Xl41118-fb58f914yfnamF55qWTbM9YPPSijO6kF51x4ZVoxum7EOkJwqsVRCe3AmVG7Yei0Yb0TZ-T1Ye-S5187LKudQvEYo0s474o1AFJpMA-C0AIzXKsKqgPo81xKxtEuVYjLewvM3hZh74qwt5YtA3tXhIWae3k8sOsnHO5TR_MVeHUEXPEujtklH8o9JyvYMVa5iwOH1dvvgNkWHzB5HEKu6u0whwe-8g-IHKba</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>18107265</pqid></control><display><type>article</type><title>Sterilizing immunity against experimental Helicobacter pylori infection is challenge-strain dependent</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Kleanthous, Harry ; Tibbitts, Timothy J ; Gray, Heather L ; Myers, Gwendolyn A ; Lee, Cynthia K ; Ermak, Thomas H ; Monath, Thomas P</creator><creatorcontrib>Kleanthous, Harry ; Tibbitts, Timothy J ; Gray, Heather L ; Myers, Gwendolyn A ; Lee, Cynthia K ; Ermak, Thomas H ; Monath, Thomas P</creatorcontrib><description>The development of a murine model of
Helicobacter pylori infection through serial in vivo passage of candidate strains has enabled a quantitative assessment of vaccine efficacy. In this study we compare infection with and protection against challenge from both CagA
+ type I, and CagA
− type II in vivo adapted isolates. In vivo passage of a type II
H. pylori isolate resulted in a highly infectious strain (X47-2AL), capable of reproducibly infecting mice to high density (10
7 CFU/g of gastric tissue). Similarly adapted type I strains were found to colonize mice at a significantly lower level (10
4–10
5 CFU/g tissue). Mucosal immunization with recombinant urease (rUre) significantly protected animals against both types. Protection against X47-2AL was characterized by a ≥100-fold (or 2 log) reduction in bacterial density. However, the presence of a residual infection highlighted the inability to achieve sterilizing immunity against this strain. The level of protection appeared independent of challenge dose, and was stable for up to 6 months, all animals exhibiting a low-level residual infection that did not recrudesce with time. Similarly immunized mice challenged with isolates representing the residual infection were also protected, confirming that they did not represent a sub-population of
H. pylori that could escape immunity. Immunization and challenge studies with type I adapted-isolates, demonstrated a similar 2–3 log reduction in the bacterial burden, but that in this instance resulted in sterilizing immunity. These results suggest varied specificity for the murine host by different
Helicobacter strains that can influence the outcome of both infection and immunity.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/S0264-410X(01)00248-1</identifier><identifier>PMID: 11535342</identifier><identifier>CODEN: VACCDE</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Administration, Oral ; Administration, Rectal ; Animals ; Animals, Outbred Strains ; Antigens, Bacterial - genetics ; Antigens, Bacterial - immunology ; Bacterial diseases ; Bacterial Proteins - analysis ; Bacterial Proteins - genetics ; Bacterial Proteins - immunology ; Bacterial Proteins - physiology ; Bacteriology ; Biological and medical sciences ; Cat Diseases - microbiology ; Cats ; Experimental bacterial diseases and models ; Fundamental and applied biological sciences. Psychology ; Gastric Mucosa - immunology ; Gastric Mucosa - microbiology ; Gastritis - microbiology ; Gastritis - therapy ; Gastritis - veterinary ; Helicobacter ; Helicobacter Infections - microbiology ; Helicobacter Infections - therapy ; Helicobacter Infections - veterinary ; Helicobacter pylori ; Helicobacter pylori - classification ; Helicobacter pylori - enzymology ; Helicobacter pylori - genetics ; Helicobacter pylori - immunology ; Helicobacter pylori - isolation & purification ; Helicobacter pylori - pathogenicity ; Immunity ; Immunization - methods ; Immunotherapy, Active ; Infectious diseases ; Macaca mulatta ; Medical sciences ; Mice ; Mice, Inbred C57BL ; Microbiology ; Monkey Diseases - microbiology ; Mouth Mucosa - immunology ; Phenotype ; Pyloric Antrum - microbiology ; Recombinant Fusion Proteins - genetics ; Recombinant Fusion Proteins - immunology ; Urease - analysis ; Urease - genetics ; Urease - physiology ; Vaccine ; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies ; Virulence - immunology</subject><ispartof>Vaccine, 2001-09, Vol.19 (32), p.4883-4895</ispartof><rights>2001 Elsevier Science Ltd</rights><rights>2002 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c422t-7b5c4548b00bdb157694632223c5783fa9fe00be1a58ef536a1a7f6add9670ba3</citedby><cites>FETCH-LOGICAL-c422t-7b5c4548b00bdb157694632223c5783fa9fe00be1a58ef536a1a7f6add9670ba3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0264410X01002481$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14153900$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11535342$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kleanthous, Harry</creatorcontrib><creatorcontrib>Tibbitts, Timothy J</creatorcontrib><creatorcontrib>Gray, Heather L</creatorcontrib><creatorcontrib>Myers, Gwendolyn A</creatorcontrib><creatorcontrib>Lee, Cynthia K</creatorcontrib><creatorcontrib>Ermak, Thomas H</creatorcontrib><creatorcontrib>Monath, Thomas P</creatorcontrib><title>Sterilizing immunity against experimental Helicobacter pylori infection is challenge-strain dependent</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>The development of a murine model of
Helicobacter pylori infection through serial in vivo passage of candidate strains has enabled a quantitative assessment of vaccine efficacy. In this study we compare infection with and protection against challenge from both CagA
+ type I, and CagA
− type II in vivo adapted isolates. In vivo passage of a type II
H. pylori isolate resulted in a highly infectious strain (X47-2AL), capable of reproducibly infecting mice to high density (10
7 CFU/g of gastric tissue). Similarly adapted type I strains were found to colonize mice at a significantly lower level (10
4–10
5 CFU/g tissue). Mucosal immunization with recombinant urease (rUre) significantly protected animals against both types. Protection against X47-2AL was characterized by a ≥100-fold (or 2 log) reduction in bacterial density. However, the presence of a residual infection highlighted the inability to achieve sterilizing immunity against this strain. The level of protection appeared independent of challenge dose, and was stable for up to 6 months, all animals exhibiting a low-level residual infection that did not recrudesce with time. Similarly immunized mice challenged with isolates representing the residual infection were also protected, confirming that they did not represent a sub-population of
H. pylori that could escape immunity. Immunization and challenge studies with type I adapted-isolates, demonstrated a similar 2–3 log reduction in the bacterial burden, but that in this instance resulted in sterilizing immunity. These results suggest varied specificity for the murine host by different
Helicobacter strains that can influence the outcome of both infection and immunity.</description><subject>Administration, Oral</subject><subject>Administration, Rectal</subject><subject>Animals</subject><subject>Animals, Outbred Strains</subject><subject>Antigens, Bacterial - genetics</subject><subject>Antigens, Bacterial - immunology</subject><subject>Bacterial diseases</subject><subject>Bacterial Proteins - analysis</subject><subject>Bacterial Proteins - genetics</subject><subject>Bacterial Proteins - immunology</subject><subject>Bacterial Proteins - physiology</subject><subject>Bacteriology</subject><subject>Biological and medical sciences</subject><subject>Cat Diseases - microbiology</subject><subject>Cats</subject><subject>Experimental bacterial diseases and models</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Gastric Mucosa - immunology</subject><subject>Gastric Mucosa - microbiology</subject><subject>Gastritis - microbiology</subject><subject>Gastritis - therapy</subject><subject>Gastritis - veterinary</subject><subject>Helicobacter</subject><subject>Helicobacter Infections - microbiology</subject><subject>Helicobacter Infections - therapy</subject><subject>Helicobacter Infections - veterinary</subject><subject>Helicobacter pylori</subject><subject>Helicobacter pylori - classification</subject><subject>Helicobacter pylori - enzymology</subject><subject>Helicobacter pylori - genetics</subject><subject>Helicobacter pylori - immunology</subject><subject>Helicobacter pylori - isolation & purification</subject><subject>Helicobacter pylori - pathogenicity</subject><subject>Immunity</subject><subject>Immunization - methods</subject><subject>Immunotherapy, Active</subject><subject>Infectious diseases</subject><subject>Macaca mulatta</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Microbiology</subject><subject>Monkey Diseases - microbiology</subject><subject>Mouth Mucosa - immunology</subject><subject>Phenotype</subject><subject>Pyloric Antrum - microbiology</subject><subject>Recombinant Fusion Proteins - genetics</subject><subject>Recombinant Fusion Proteins - immunology</subject><subject>Urease - analysis</subject><subject>Urease - genetics</subject><subject>Urease - physiology</subject><subject>Vaccine</subject><subject>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies</subject><subject>Virulence - immunology</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU1v1DAQhi0EotvCTwD5AiqHgMefyalCFVCkShwKEjfLcSaLkeMEO4tYfj1ud0WPPfkwzztjPS8hL4C9BQb63Q3jWjYS2PdzBm8Y47Jt4BHZQGtEwxW0j8nmP3JCTkv5yRhTArqn5ARACSUk3xC8WTGHGP6GtKVhmnYprHvqti6kslL8s9TphGl1kV5hDH7una8JuuzjnAMNaUS_hjnRUKj_4WLEtMWmrLkuoAMumIaafkaejC4WfH58z8i3jx--Xl41118-fb58f914yfnamF55qWTbM9YPPSijO6kF51x4ZVoxum7EOkJwqsVRCe3AmVG7Yei0Yb0TZ-T1Ye-S5187LKudQvEYo0s474o1AFJpMA-C0AIzXKsKqgPo81xKxtEuVYjLewvM3hZh74qwt5YtA3tXhIWae3k8sOsnHO5TR_MVeHUEXPEujtklH8o9JyvYMVa5iwOH1dvvgNkWHzB5HEKu6u0whwe-8g-IHKba</recordid><startdate>20010914</startdate><enddate>20010914</enddate><creator>Kleanthous, Harry</creator><creator>Tibbitts, Timothy J</creator><creator>Gray, Heather L</creator><creator>Myers, Gwendolyn A</creator><creator>Lee, Cynthia K</creator><creator>Ermak, Thomas H</creator><creator>Monath, Thomas P</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T5</scope><scope>C1K</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20010914</creationdate><title>Sterilizing immunity against experimental Helicobacter pylori infection is challenge-strain dependent</title><author>Kleanthous, Harry ; Tibbitts, Timothy J ; Gray, Heather L ; Myers, Gwendolyn A ; Lee, Cynthia K ; Ermak, Thomas H ; Monath, Thomas P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c422t-7b5c4548b00bdb157694632223c5783fa9fe00be1a58ef536a1a7f6add9670ba3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Administration, Oral</topic><topic>Administration, Rectal</topic><topic>Animals</topic><topic>Animals, Outbred Strains</topic><topic>Antigens, Bacterial - genetics</topic><topic>Antigens, Bacterial - immunology</topic><topic>Bacterial diseases</topic><topic>Bacterial Proteins - analysis</topic><topic>Bacterial Proteins - genetics</topic><topic>Bacterial Proteins - immunology</topic><topic>Bacterial Proteins - physiology</topic><topic>Bacteriology</topic><topic>Biological and medical sciences</topic><topic>Cat Diseases - microbiology</topic><topic>Cats</topic><topic>Experimental bacterial diseases and models</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Gastric Mucosa - immunology</topic><topic>Gastric Mucosa - microbiology</topic><topic>Gastritis - microbiology</topic><topic>Gastritis - therapy</topic><topic>Gastritis - veterinary</topic><topic>Helicobacter</topic><topic>Helicobacter Infections - microbiology</topic><topic>Helicobacter Infections - therapy</topic><topic>Helicobacter Infections - veterinary</topic><topic>Helicobacter pylori</topic><topic>Helicobacter pylori - classification</topic><topic>Helicobacter pylori - enzymology</topic><topic>Helicobacter pylori - genetics</topic><topic>Helicobacter pylori - immunology</topic><topic>Helicobacter pylori - isolation & purification</topic><topic>Helicobacter pylori - pathogenicity</topic><topic>Immunity</topic><topic>Immunization - methods</topic><topic>Immunotherapy, Active</topic><topic>Infectious diseases</topic><topic>Macaca mulatta</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Microbiology</topic><topic>Monkey Diseases - microbiology</topic><topic>Mouth Mucosa - immunology</topic><topic>Phenotype</topic><topic>Pyloric Antrum - microbiology</topic><topic>Recombinant Fusion Proteins - genetics</topic><topic>Recombinant Fusion Proteins - immunology</topic><topic>Urease - analysis</topic><topic>Urease - genetics</topic><topic>Urease - physiology</topic><topic>Vaccine</topic><topic>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies</topic><topic>Virulence - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kleanthous, Harry</creatorcontrib><creatorcontrib>Tibbitts, Timothy J</creatorcontrib><creatorcontrib>Gray, Heather L</creatorcontrib><creatorcontrib>Myers, Gwendolyn A</creatorcontrib><creatorcontrib>Lee, Cynthia K</creatorcontrib><creatorcontrib>Ermak, Thomas H</creatorcontrib><creatorcontrib>Monath, Thomas P</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Immunology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kleanthous, Harry</au><au>Tibbitts, Timothy J</au><au>Gray, Heather L</au><au>Myers, Gwendolyn A</au><au>Lee, Cynthia K</au><au>Ermak, Thomas H</au><au>Monath, Thomas P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sterilizing immunity against experimental Helicobacter pylori infection is challenge-strain dependent</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2001-09-14</date><risdate>2001</risdate><volume>19</volume><issue>32</issue><spage>4883</spage><epage>4895</epage><pages>4883-4895</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><coden>VACCDE</coden><abstract>The development of a murine model of
Helicobacter pylori infection through serial in vivo passage of candidate strains has enabled a quantitative assessment of vaccine efficacy. In this study we compare infection with and protection against challenge from both CagA
+ type I, and CagA
− type II in vivo adapted isolates. In vivo passage of a type II
H. pylori isolate resulted in a highly infectious strain (X47-2AL), capable of reproducibly infecting mice to high density (10
7 CFU/g of gastric tissue). Similarly adapted type I strains were found to colonize mice at a significantly lower level (10
4–10
5 CFU/g tissue). Mucosal immunization with recombinant urease (rUre) significantly protected animals against both types. Protection against X47-2AL was characterized by a ≥100-fold (or 2 log) reduction in bacterial density. However, the presence of a residual infection highlighted the inability to achieve sterilizing immunity against this strain. The level of protection appeared independent of challenge dose, and was stable for up to 6 months, all animals exhibiting a low-level residual infection that did not recrudesce with time. Similarly immunized mice challenged with isolates representing the residual infection were also protected, confirming that they did not represent a sub-population of
H. pylori that could escape immunity. Immunization and challenge studies with type I adapted-isolates, demonstrated a similar 2–3 log reduction in the bacterial burden, but that in this instance resulted in sterilizing immunity. These results suggest varied specificity for the murine host by different
Helicobacter strains that can influence the outcome of both infection and immunity.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>11535342</pmid><doi>10.1016/S0264-410X(01)00248-1</doi><tpages>13</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0264-410X |
ispartof | Vaccine, 2001-09, Vol.19 (32), p.4883-4895 |
issn | 0264-410X 1873-2518 |
language | eng |
recordid | cdi_proquest_miscellaneous_71145617 |
source | MEDLINE; Elsevier ScienceDirect Journals Complete |
subjects | Administration, Oral Administration, Rectal Animals Animals, Outbred Strains Antigens, Bacterial - genetics Antigens, Bacterial - immunology Bacterial diseases Bacterial Proteins - analysis Bacterial Proteins - genetics Bacterial Proteins - immunology Bacterial Proteins - physiology Bacteriology Biological and medical sciences Cat Diseases - microbiology Cats Experimental bacterial diseases and models Fundamental and applied biological sciences. Psychology Gastric Mucosa - immunology Gastric Mucosa - microbiology Gastritis - microbiology Gastritis - therapy Gastritis - veterinary Helicobacter Helicobacter Infections - microbiology Helicobacter Infections - therapy Helicobacter Infections - veterinary Helicobacter pylori Helicobacter pylori - classification Helicobacter pylori - enzymology Helicobacter pylori - genetics Helicobacter pylori - immunology Helicobacter pylori - isolation & purification Helicobacter pylori - pathogenicity Immunity Immunization - methods Immunotherapy, Active Infectious diseases Macaca mulatta Medical sciences Mice Mice, Inbred C57BL Microbiology Monkey Diseases - microbiology Mouth Mucosa - immunology Phenotype Pyloric Antrum - microbiology Recombinant Fusion Proteins - genetics Recombinant Fusion Proteins - immunology Urease - analysis Urease - genetics Urease - physiology Vaccine Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies Virulence - immunology |
title | Sterilizing immunity against experimental Helicobacter pylori infection is challenge-strain dependent |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T06%3A58%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sterilizing%20immunity%20against%20experimental%20Helicobacter%20pylori%20infection%20is%20challenge-strain%20dependent&rft.jtitle=Vaccine&rft.au=Kleanthous,%20Harry&rft.date=2001-09-14&rft.volume=19&rft.issue=32&rft.spage=4883&rft.epage=4895&rft.pages=4883-4895&rft.issn=0264-410X&rft.eissn=1873-2518&rft.coden=VACCDE&rft_id=info:doi/10.1016/S0264-410X(01)00248-1&rft_dat=%3Cproquest_cross%3E18107265%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=18107265&rft_id=info:pmid/11535342&rft_els_id=S0264410X01002481&rfr_iscdi=true |